Cost-effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

被引：0
|
作者：
Shah, Shimoli V. [1 ]
Gage, Brian F. [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
来源：
CIRCULATION | 2010年 / 122卷 / 21期
关键词：
Cost-effectiveness; Atrial fibrillation; Thrombin inhibitors; Stroke; Anticoagulants;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A16179
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of amiodarone prophylaxis for atrial fibrillation following cardiac surgery
    Barnes, BJ
    Grauer, DW
    Howard, PA
    Kirkland, EA
    Gorton, ME
    Kramer, JB
    Muehlebach, GF
    Reed, WA
    CIRCULATION, 2005, 111 (20) : E317 - E318
  • [42] Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
    You, Joyce H. S.
    Tsui, Kia K. N.
    Wong, Raymond S. M.
    Cheng, Gergory
    PLOS ONE, 2012, 7 (06):
  • [43] Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
    Chevalier, Julie
    Delaitre, Olivier
    Hammes, Florence
    de Pouvourville, Gerard
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2014, 107 (6-7) : 381 - 390
  • [44] Improve Warfarin Therapy or Use Dabigatran for Patients with Atrial Fibrillation - A Cost-Effectiveness Analysis
    You, Joyce H.
    Tsui, Kia K.
    Wong, Raymond S.
    Cheng, Gregory
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1334 - 1334
  • [45] ANALYSIS OF COST-EFFECTIVENESS OF WARFARIN VS. DABIGATRAN ETEXILATE IN ATRIAL FIBRILLATION IN ECUADOR
    Penaherrera, E.
    Tettamanti, D.
    Aguirre, F.
    Puyol, L. F.
    Cardenas, E.
    Torres, G.
    Herran, S.
    VALUE IN HEALTH, 2015, 18 (07) : A830 - A830
  • [46] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [47] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [48] STROKE PROPHYLAXIS WITH WARFARIN AND DABIGATRAN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION - A COST ANALYSIS
    Ali, A. N.
    Bailey, C.
    Abdulhafiz, A. H.
    AGE AND AGEING, 2013, 42 : 31 - 31
  • [49] THE COST-EFFECTIVENESS OF SCREENING FOR SILENT ATRIAL FIBRILLATION AFTER ISCHAEMIC STROKE
    Levin, L. A.
    Husberg, M.
    Rosenqvist, M.
    Sobosinski-Doliwa, P.
    Friberg, L.
    Frykman-Kull, V
    Davidson, T.
    VALUE IN HEALTH, 2013, 16 (07) : A527 - A527
  • [50] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Kapur, A. K.
    Chatzitheofilou, I
    Schang, L. K.
    VALUE IN HEALTH, 2012, 15 (04) : A122 - A122
12345